Emergent BioSolutions | Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 168.71M 104K 2025-09
Akebia Therapeutics USD 2K 0 2025-03
ALKERMES USD 165.1M 49K 2025-09
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.8M 28K 2025-09
ANI Pharmaceuticals USD 21.73M 21.73M 2025-06
BioMarin Pharmaceutical USD 192.1M 97K 2025-09
Coherus Biosciences USD 12K 0 2025-03
Emergent BioSolutions USD 100K 0 2023-06
Exact Sciences USD 189.45M 232K 2025-09
Exelixis USD 268.1M 2.03M 2025-09
Glaxosmithkline GBP 4.03B 2.68B 2025-09
Heron Therapeutics USD 1.52M 14K 2024-09
Ionis Pharmaceuticals USD 161.14M 160.98M 2025-09
Ironwood Pharmaceuticals USD 160K 0 2024-12
Lonza CHF 72M 0 2024-12
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Myriad Genetics USD 93.1M 0 2025-09
Nektar Therapeutics USD 19K 0 2024-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Pacira USD 44.9M 44.85M 2025-06
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 79.93M 554K 2025-09
Sarepta Therapeutics USD 104.77M 7.06M 2025-09
United Therapeutics USD 42.9M 42.1M 2025-09
Vanda Pharmaceuticals USD 58K 0 2024-12
Xoma USD 87K 1000 2024-06


Emergent BioSolutions Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.